Deutsche Bank AG Sells 9,172 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Deutsche Bank AG trimmed its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 10.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 76,777 shares of the company’s stock after selling 9,172 shares during the quarter. Deutsche Bank AG owned 0.13% of Harmony Biosciences worth $2,548,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in HRMY. Deep Track Capital LP bought a new position in Harmony Biosciences in the fourth quarter worth about $49,894,000. Dimensional Fund Advisors LP boosted its position in Harmony Biosciences by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,213,029 shares of the company’s stock worth $41,739,000 after purchasing an additional 160,490 shares in the last quarter. LSV Asset Management boosted its position in Harmony Biosciences by 25.0% in the 1st quarter. LSV Asset Management now owns 1,194,961 shares of the company’s stock worth $39,661,000 after purchasing an additional 238,744 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Harmony Biosciences by 66.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company’s stock worth $17,205,000 after buying an additional 200,000 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of Harmony Biosciences by 35.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 480,605 shares of the company’s stock worth $16,538,000 after buying an additional 124,656 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $36.40 on Wednesday. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of 11.74, a PEG ratio of 0.43 and a beta of 0.84. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.84 and a quick ratio of 3.80. The business has a 50-day moving average of $34.27 and a 200-day moving average of $33.69.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The company had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. During the same quarter in the previous year, the company posted $1.05 earnings per share. The firm’s revenue for the quarter was up 16.0% compared to the same quarter last year. Harmony Biosciences has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Cantor Fitzgerald raised Harmony Biosciences to a “strong-buy” rating in a research note on Tuesday, May 13th. UBS Group reduced their price target on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, April 28th. The Goldman Sachs Group initiated coverage on Harmony Biosciences in a research report on Thursday, July 10th. They set a “neutral” rating and a $33.00 target price on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $55.00 price target (up previously from $54.00) on shares of Harmony Biosciences in a research report on Thursday, July 10th. Finally, Mizuho lifted their price target on Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $51.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.